Weight-loss jabs for obese kids 'are effective and help prevent mealtime rows'
Experts presented the findings at the European Congress on Obesity in Malaga, Spain.
They found that the drugs helped obese youngsters lose weight on top of a diet and lifestyle plan.
Weight-loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.
They are available on the NHS for adults with a high body mass index (BMI) or through private providers.
The National Institute for Health and Care Excellence (Nice) stopped its appraisal of semaglutide (Wegovy) for use in 12 to 17-year-olds after the manufacturer, Novo Nordisk, said it was unable to provide evidence for submission.
In certain instances where there is a proven clinical need, specialist paediatric clinics can prescribe weight-loss injections.
Dr Annika Janson, from Karolinska University Hospital in Sweden, presented the new research.
She said: "GLP-1 drugs are increasingly used to treat obesity in adults.
"They can also be used in children from the age of 12 and clinical trials have shown children lose 5-16% of their body weight after a year of treatment."
Alongside this, Dr Janson said the jabs had results "beyond obesity".
"The families reported reduced conflicts around food and improved capacity for other lifestyle adaptations," she said.
She added: "It was easier to stick to meals and limit snacks. Portions could be downsized. For some children, not being hungry all the time is a new feeling."
Side effects of weight-loss drugs include nausea, diarrhoea, stomach cramps and vision problems.
A spokesperson for Novo Nordisk said the company hadn't submitted evidence for Nice appraisal because it lacked "utility data and risk equations in linking weight loss in adolescents to long-term outcomes."
It added that, at this time, it had no intention of making an evidence submission.
Last year, said that children in the UK were getting shorter, fatter and sicker due to "shocking levels" of poverty and food deprivation.
It found that among 10 to 11-year-olds had increased by 30% since 2006, with one in five children classed as obese by the time they leave primary school.
It comes as new data presented by Novo Nordisk showed that Wegovy for adults could help protect against heart disease in the earliest stages.
Read more from Sky News:
Alongside this, it was said to cut the risk of heart attack, stroke or early death in high-risk patients.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
Man with rare ‘boob' condition is scared to take his top off while dating
A man with 'boobs' due to a rare condition is raising $8,741 (£6.5k) to have them removed – because he is too conscious to take his top off on dates. Thabo Methie, 31, was just 10 years old when he first started noticing he was developing breasts instead of pecks. Sporty Thabo says he was bullied at school, with kids saying they were 'bigger than some of the females.' Thabo stopped participating in sports like swimming at age 11 as he was too self-conscious to take off his top, and he says he became 'sick' of being the brunt of every joke. He went to the doctors and was diagnosed with gynaecomastia – an increase in the amount of breast gland tissue in boys or men. 6 Thabo Methie, 31, was just 10 years old when he first started noticing he was developing breasts instead of pecks. Thabo Methie / SWNS Having lived with the condition for 21 years and worn oversized t-shirts to hide his chest, Thabo has decided that enough is enough. As the surgery is deemed cosmetic, Thabo says it can't be done through the NHS. Instead, he's set up a GoFundMe to raise the $8,741 (£6.5k) required for 'life-changing' private surgery to remove the breast tissue he says has been holding him back for years. Thabo, a healthcare assistant for the NHS blood and transplant service, originally from Marondera, Zimbabwe, but living in Nottingham, Nottinghamshire, said: 'It's not painful, but it has mentally affected me because of how people were to me. 6 Thabo says he was bullied at school, with kids saying they were 'bigger than some of the females.' Thabo Methie / SWNS 'I went for quite a while without dating someone because I didn't want to take my clothes off. 'For such a long time, I would debate getting a knife and cutting it off myself. 'The moment people started making jokes, that really hurt me, and that stuck with me, especially when people pointed them out to me. 'Some girls were laughing about it at school, and the most heartbreaking one was my then-crush telling me that I could breastfeed.' 6 He went to the doctors and was diagnosed with gynaecomastia – an increase in the amount of breast gland tissue in boys or men. Thabo Methie / SWNS When Thabo was 13, he attended boarding school, where his insecurities grew and he became a recluse, trying to avoid any interaction with his peers. He went on to spend the next four years trying to wash when no one would see him, which proved difficult, sharing a communal bathroom with 23 other people. Start your day with all you need to know Morning Report delivers the latest news, videos, photos and more. Thanks for signing up! Enter your email address Please provide a valid email address. By clicking above you agree to the Terms of Use and Privacy Policy. Never miss a story. Check out more newsletters Thabo said: 'My entire life has been about wearing clothes that hide something that makes me deeply embarrassed, and has gotten worse with time. 'Even now, when I want to swim, I worry what people will think of me, and I want my confidence to come back, and I don't want to worry about what other people think of me.' 6 Having lived with the condition for 21 years and worn oversized t-shirts to hide his chest, Thabo has decided that enough is enough. Thabo Methie / SWNS When Thabo was 19, he started to go running to try and prevent his chest from growing any bigger, which actually helped him to an extent. Thabo said, 'This has been ruining my self-esteem, and it's just making me feel depressed most of the time. 'I have added strength training to the running, but these can only do so much, especially as I gain weight. 6 Thabo Methie set up a GoFundMe to raise the $8,741 (£6.5k) required for 'life-changing' private surgery to remove the breast tissue he says has been holding him back for years. Thabo Methie / SWNS 'I started eating healthier with food that has more fibre, and last year I started taking the weight loss injection, but I stopped taking it as it was really expensive.' Thabo's condition is thought to be linked to a hormone imbalance and has significantly impacted his life for over two decades. Though he's maintained an active lifestyle to try and manage it, he has gained 21kg and now weights 19st – and still wears XXXL t-shirts. The breast tissue has grown more with time, affecting his self-esteem and mental health, he said. 6 Methie's condition is thought to be linked to a hormone imbalance and has significantly impacted his life for over two decades. Thabo Methie / SWNS The NHS classifies the surgery as cosmetic and requires long-term UK-based medical records, which Thabo cannot provide due to his recent arrival on a visa since moving to the UK in 2023. Thabo said: 'To have this surgery would mean the world to me. It would be a huge weight off of my shoulders. 'I really hope the surgery can be as soon as possible. When I raise enough money, I will be booking the surgery straight away.'
Newsweek
4 hours ago
- Newsweek
Weight-Loss Drugs Telehealth Platform Hims & Hers Hit With New Lawsuit
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A stockholder has filed a derivative lawsuit against the board of directors of Hims & Hers, the fast‑growing telehealth platform best known for men's and women's health products—especially its weight‑loss therapies. The suit Jones vs. Dudum names board members and CEO Andrew Dudum in U.S. District Court in San Francisco, arguing that a high-profile partnership gone awry has left the company—and its shareholders—on shaky ground. Newsweek contacted Francis J. Flynn, Jr., Attorney at the Law Office of Francis J. Flynn, Jr. representing Steven Jones in this derivative action on behalf of Hims & Hers Health, Inc., via email on Tuesday for comment. Attorneys for Dudum or the others directors was not listed at time of publication. Dudum, responding to the deal's collapse, last month said Hims & Hers adhered to legal frameworks and accused, accused the drugmaker involved of attempting to steer the company's patients toward its own products. "We refuse to be strong-armed," he said. The other company in the deal Novo Nordisk did not respond to Dudum's remarks, when contacted by Reuters on June 23. Stock image of semaglutide injections. A recent TikTok explained whether you would gain back double the weight after going off weight-loss drugs. Stock image of semaglutide injections. A recent TikTok explained whether you would gain back double the weight after going off weight-loss drugs. Photo by Aplott / Getty Images Why It Matters The dispute raises critical questions for the telehealth industry, including regulatory gray zones such as how far can compounding pharmacies can go under "personalization" rules, especially when dealing in high-demand drugs? And what responsibility do boards have to fully evaluate regulatory risk—even when pursuing innovative deals? What To Know The newly filed lawsuit is not a standard stock drop claim but a derivative suit, meaning it is brought by a shareholder on behalf of the company. A derivative suit places emphasis not just on damages to investors, but on the breach of fiduciary duty owed to the company itself. If the suit is successful, any recovery—whether from settlements or judgments—will go to Hims & Hers, not directly to the suing shareholder. Jones vs. Dudum is the latest of three investor‑initiated lawsuits tied to the collapse of the Wegovy deal. Two earlier securities class action suits were filed last month by investors seeking damages for the sharp drop in share price following the June meltdown. Unlike those class actions—which typically focus on misrepresentation to shareholders—the derivative suit alleges governance failures and corporate mismanagement at the board level. The plaintiff in the new suit alleges that the board and management disseminated misleading statements about the health of a partnership and the legality of its business model, ultimately harming the company's interests. The claim hinges on two major points: first, that the board approved a deal without sufficient due diligence into regulatory exposure; second, that public communications misled investors about the risk of compounding semaglutide and the deal's longevity. Ozempic and rival products like Danish pharmaceutical giant Novo Nordisk's Wegovy have fueled a national obsession with medical weight loss. But pandemic-related demand spikes and supply constraints prompted the FDA to allow compounding pharmacies to produce semaglutide during shortages. While legal, these compounded drugs are not subject to the same regulatory oversight, raising red flags for safety advocates and brand-name drugmakers. Once the shortage was lifted in February 2025, the FDA removed approved semaglutide from its shortage list, signaling that broad compounding should cease. Instead, many including Hims & Hers continued dispensing compounding-based copies under the contested "personalization" rationale—offering customised semaglutide dosages providers argue are tailored to individual patient needs. On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The goal was to tap into soaring demand for obesity treatments via a trusted telehealth interface. At the time, Hims & Hers had also been offering compounded semaglutide, a so-called "knock‑off" version of Wegovy, legally produced by compounding pharmacies during the FDA's declared shortage of brand‑name drugs—an arrangement that Novo Nordisk had publicly criticized and challenged as risky and unregulated. In an abrupt June 23 announcement—only two months after the deal was unveiled—Novo Nordisk severed the partnership. The company accused Hims & Hers of "deceptive promotion," arguing that its compounding operations went beyond legal allowances and threatened patient safety. Hims & Hers' stock plummeted. What People Are Saying Him & Hers Founder, Andrew Dudum said in his post on X in June: "In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients", adding "We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice." Dudum said of the prospect of legal action: "They might take legal action. Others might take legal action. Again, when things are hurting their bottom line in this way, people do all types of things." Dave Moore, executive vice president U.S. operations at Novo Nordisk said in a June 23 release about the deal collapse: "We terminated the deal to protect patients living with obesity", and reaffirmed that only "...authentic, FDA‑approved and regulated Wegovy should be prescribed." He added: "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety—and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." And in a Novo corporate statement on July 14, the company said: "Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk." What Happens Next The derivative lawsuit is in its early stage. No hearings or settlement discussions have been reported.
Medscape
6 hours ago
- Medscape
NICE Widens Access to Ribociclib for Early Breast Cancer
The National Institute for Health and Care Excellence (NICE) has recommended ribociclib (Kisqali, Novartis) for routine NHS use in adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer in patients at high risk of recurrence. The drug is now recommended for use alongside an aromatase inhibitor after initial treatments, such as surgery. In pre-menopausal women, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone agonist. Targeted Therapy for Common Breast Cancer Subtype Ribociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by blocking proteins that drive cancer cell growth and division. NICE said the treatment 'represents a significant advance' in managing hormone receptor-positive, HER2-negative early breast cancer. Breast cancer is the most common cancer in the UK. Hormone receptor-positive, HER2-negative breast cancer is the most common subtype, accounting for about 68% of all UK cases. Expanded NHS Use Follows Evidence Submission Until now, NHS access in England was limited to patients whose cancer had spread to nearby lymph nodes. NICE approved this use of ribociclib in April 2025 but asked Novartis for more evidence to justify broader access. Following further review, NICE concluded in final draft guidance that ribociclib with an aromatase inhibitor offers clinical benefit and value for money. It is now considered a cost-effective use of NHS resources. Trial Shows Delayed Recurrence A clinical trial involving more than 5000 patients showed that ribociclib combined with an aromatase inhibitor delayed disease recurrence compared with the aromatase inhibitor alone. The latest analysis, based on a mean of 33 months' follow-up, continued to show improved invasive disease-free survival across key subgroups. However, NICE said that it remained unclear whether the combination increased overall survival and that more mature data, including predictions of longer-term outcomes, is needed. Further data from the trial are expected in May 2026. Comparable to Other Options Indirect evidence suggests that ribociclib plus an aromatase inhibitor is as effective as abemaciclib plus endocrine therapy. Abemaciclib is currently used for node-positive breast cancer. Ribociclib in combination with fulvestrant is already recommended for treating hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy. This demonstrated 'the drug's versatility across different stages of the disease,', NICE said. Helen Knight, director of medicines evaluation at NICE, described the latest decision as 'fantastic news for the tens of thousands of patients and their loved ones'. An estimated 5700 people with early breast cancer could benefit from expanded access to the combination treatment. Relapse after initial treatment occurs in about 30% of people with early breast cancer. Patient experts told the NICE committee that the high risk of recurrence has a considerable impact on quality of life. 'The fear of the cancer returning is a common cause of stress and anxiety for people and their families, affecting physical and psychological wellbeing,' they said. Treatment options are limited and have unpleasant side effects. Having different options is particularly important because people often choose treatments based on their side-effect profiles. Both patient and clinical experts emphasised the importance of treatment choice. Dosage, Side Effects, and Pricing Ribociclib is taken orally, which may improve convenience and adherence compared with alternatives. The usual dose of ribociclib is: 400 mg once daily (two 200 mg tablets) for primary breast cancer 600 mg once daily (three 200 mg tablets) for locally advanced or secondary disease Common side effects include leukopaenia and increased infection risks, anaemia, anorexia, nausea and vomiting, diarrhoea and constipation, abdominal pain, fatigue, sore mouth, shortness of breath, cough, rashes, and hair loss. The list prices of ribociclib 200-mg tablets are: £983.33 for 21 tablets £1966.67 for 42 tablets £2950.00 for 63 tablets A simple patient access scheme allows the NHS to purchase the drug at a confidential discount. Knight said the expanded access was 'also due in no small part to the willingness of companies to engage with us constructively, as in the case with ribociclib, to ensure the benefits of their treatments are properly presented and appropriately priced'.
